GSK plc (LON:GSK)
1,862.50
+34.00 (1.86%)
Jan 27, 2026, 4:56 PM GMT
GSK plc Revenue
GSK plc had revenue of 8.55B GBP in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 32.17B, up 10.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 7.00% growth.
Revenue (ttm)
32.17B
Revenue Growth
+10.59%
P/S Ratio
2.32
Revenue / Employee
468.69K
Employees
68,629
Market Cap
74.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 2.05B | 7.00% |
| Dec 31, 2022 | 29.32B | -4.43B | -13.12% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 6.26B | 26.18% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
GSK plc News
- 1 day ago - GSK (GSK) Leverages AI in Drug Development for Improved Efficiency - GuruFocus
- 1 day ago - GSK Receives European Approval for Arexvy RSV Vaccine for Adults - GuruFocus
- 1 day ago - GSK: Arexvy Vaccine Receives European Commission Approval For Use In All Adults - Nasdaq
- 3 days ago - Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more - Seeking Alpha
- 4 days ago - GSK Secures Approval in China for Trelegy Ellipta in Asthma Treatment - GuruFocus
- 4 days ago - GSK (GSK) Gains Approval in China for Asthma Treatment - GuruFocus
- 4 days ago - China approves GSK’s Trelegy Ellipta for adult asthma treatment - Seeking Alpha
- 5 days ago - FINANCIAL CONSULATE, INC Buys 215 Shares of GSK PLC (GSK) - GuruFocus